Gary C. Du MoulinMS, PhD, MPH
Gary C. du Moulin, PhD, MPH recently retired as Senior Director of Quality Aseptic Control for Genzyme (A Sanofi Company) where he participated in the development and execution of robust quality systems for Genzyme’s products including biologics and cell based therapies. Dr. du Moulin joined Genzyme in 1995 after working for six years developing quality systems for cellular therapies for the treatment of renal cell carcinoma. Prior to his industrial experience, he spent 15 years on the faculty of Harvard Medical School in the Department of Anesthesia at Beth Israel Hospital.
He has more than 150 publications in the areas of microbiology, epidemiology, and the regulation and quality control of living cells as a therapeutic modality. Dr. du Moulin received his BS in 1969 from Norwich University, an MS degree from Northeastern University, and MPH and PhD degrees from Boston University. Dr. du Moulin has served on U.S. Pharmacopoeia’s General Chapters Biological Analysis and Gene Therapy, Cell Therapy, and Tissue Engineering Expert Committees and chaired the ad hoc advisory panel for fetal bovine serum.
He currently serves on the Modern Microbiological Methods Expert Panel. He serves on the editorial board of Regenerative Medicine and is RAC certified and past Chairman of the Editorial Board of the Regulatory Affairs Professionals Society Magazine, RAPS Focus and was appointed to the Grants Review Working Group of the California Institute for Regenerative Medicine. He is retired from the U.S. Army Reserve at the rank of Colonel after 38 years of service and currently teaches at the Massachusetts College of Pharmacy and Health Sciences University in Boston as Adjunct Associate Professor of Drug Regulatory Affairs.